Market Overview:
For metastatic castrate-resistant prostate cancer, the best treatment is to begin hormone therapy. This is a standard treatment for early-stage prostate cancer and is effective for many men. However, if the disease has spread to other parts of the body, hormone therapy will not be an effective solution. In this case, patients will need a combination of drugs to combat cancer. A combination of hormone therapy and chemotherapy will be necessary for the best chance of survival. A new treatment is now available for patients with mCRPC. Berzosertib, an inhibitor of the DNA-repair protein ATR, is being studied in a clinical trial for this type of cancer. It is also being investigated as a monotherapy for metastatic castrate-resistant prostate cancer. This treatment is effective for many men with advanced mCRPC and is still under investigation for its effectiveness.
𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 @
https://www.coherentmarketinsights.com/insight/request-sample/4529
Competitive Landscape:
• Pfizer Inc,
• Dendreon Pharmaceuticals LLC,
• Bayer AG,
• Johnson & Johnson,
• Sanofi,
Key Market Drivers:
The increasing incidence of prostate cancer in the world is expected to drive the growth of the global castrate-resistant prostate cancer market. For instance, according to World Health Organization (WHO), prostate cancer is the 3rd most commonly diagnosed cancer globally. In 2020, there were around 1,414,259 prostate cancer cases in the world. There are many treatment options available for individuals suffering from prostate cancer. These include surgery, hormone therapy, and nonsurgical therapies.
However, because prostate cancer is so hard to treat, it is usually best left to the doctor. The type of treatment patients receive will depend on the stage of the disease and how aggressively it is spread. In some cases, they may need a combination of treatments. The more aggressive types of the disease can spread quickly, so early diagnosis is vital. The more advanced stages of the disease require the most extensive treatment. Fortunately, most forms of this cancer can be cured with the proper diagnosis. The increasing introduction of new prostate cancer treatments is estimated to propel the growth of the global castrate-resistant prostate cancer market.
Request PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/4529
Covid-19 Impact Analysis:
During the COVID-19 pandemic, the increasing focus on the treatment options for curbing the rapid spread of the virus hindered the focus on other chronic diseases such as cancer and hence disrupted the growth of the global castrate-resistant prostate cancer. Moreover, transport restrictions and less availability of hospital beds also affected the market growth.
Key Takeaways:
North America is expected to hold a major share of the global castrate-resistant prostate cancer market, owing to the increasing prevalence of prostate cancer in the region. For instance, according to the American Cancer Society, currently, there are around 268,490 new cases of prostate cancer in the U.S.
The Asia Pacific is estimated to witness high growth in the global castrate-resistant prostate cancer market, owing to the increasing prevalence of cancer care hospitals in the region. For instance, according to Business Line, in 2018, there were around 1250 oncologists in India.
Reasons to Buy this Castrate-resistant Prostate Cancer Market Report
➡ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Castrate-resistant Prostate Cancer market
➡Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Castrate-resistant Prostate Cancer market
➡Leading company profiles reveal details of key Castrate-resistant Prostate Cancer market players emerging five operations and financial performance
➡Add weight to presentations and pitches by understanding the future growth prospects of the emerging Castrate-resistant Prostate Cancer market with five year historical forecasts
➡Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region .
Buy This Complete Business Report @
https://www.coherentmarketinsights.com/insight/buy-now/4529
Table of Content
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Therapy type
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Porter’s Analysis
- Industry Trends
- Key Highlights
- Epidemiology
- Reimbursement Scenario
- Regulatory Scenario
- Product Launch and Approvals
- Acquisition and Collaboration Scenario
- Market Dynamics
- Global Castrate-resistant Prostate Cancer Market – Impact of Coronavirus (Covid-19) Pandemic
- COVID-19 Epidemiology
- Impact of COVID-19 on Demand and Supply of Castrate-Resistant Prostate Cancer Treatment
- Impact of COVID-19 on the overall Healthcare Sector
- Global Castrate-resistant Prostate Cancer Market, By Therapy Type, 2017-2028 (US$ Billion)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Hormonal Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Billion)
- Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Billion)
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Billion)
- Introduction
- Global Castrate-resistant Prostate Cancer Market, By Drug Class, 2017 – 2028 (US$ Billion)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Antineoplastic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Billion)
- Non-steroidal Antiandrogen
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Billion)
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Billion)
- Microtubule Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Billion)
- Introduction
- Global Castrate-resistant Prostate Cancer Market, By Route of Administration, 2017 – 2028 (US$ Billion)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Billion)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Billion)
- Introduction
- Global Castrate-resistant Prostate Cancer Market, By Distribution Channel, 2017 – 2028 (US$ Billion)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Billion)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Billion)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Billion)
- Introduction
- Global Castrate-resistant Prostate Cancer Market, By Region, 2017 – 2028 (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2018 – 2028
- Regional Trends
- North America
- Market Size and Forecast, By Therapy Type, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Drug Class, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Route of Administration, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Country, 2017 – 2028 (US$ Bn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Therapy Type, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Drug Class, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Route of Administration, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Country, 2017 – 2028 (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Therapy Type, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Drug Class, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Route of Administration, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Country, 2017 – 2028 (US$ Bn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Therapy Type, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Drug Class, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Route of Administration, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Country, 2017 – 2028 (US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Therapy Type, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Drug Class, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Route of Administration, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Country, 2017 – 2028 (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Therapy Type, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Drug Class, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Route of Administration, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Bn)
- Market Size and Forecast, By Country/Region, 2017 – 2028 (US$ Bn)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Company Profiles
- Sanofi*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Johnson & Johnson Services Inc.
- Pfizer Inc.
- Astellas Pharma Inc.
- Bayer AG
- Bristol Myers Squibb
- Merck Sharp & Dohme
- Novartis International AG
- Eli Lilly & Company
- AstraZeneca plc.
- Sanofi*
- Company Profiles
*Key pointers provided are also applicable to other companies covered in the scope of the report.
-
- Analyst Views
- Section
- Research Methodology
- About us
- Contact
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837